Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

Spinal Cord Injuries Clinical Trial

— CASPER  

Official title:

Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03911492
• Other study ID #: H19-00805
• Status: Recruiting
• Phase: N/A
• Start date: August 31, 2019
• Est. completion date: December 2025

Study information

• Verified date: June 2023
• Source: University of British Columbia
• Contact: Allan Aludino
• Phone: 604-875-4111
• Email: allan.aludino[@]vch.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multicenter study will enroll 100 patients with acute traumatic cervical and thoracic SCI who have a lumbar intrathecal catheter inserted within 24 hours of their injury. The lumbar intrathecal catheter will be inserted pre-operatively for the measurement of ITP and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between MAP and the ITP. There are two important distinct yet related objectives in this prospective interventional study. 1. Determine the effect of SCPP maintenance ≥ 65 mmHg in acute SCI on neurologic recovery as measured by ASIA Impairment Scale (AIS) grade conversion and motor score improvement. 2. Collect CSF and blood samples for the measurement of neurochemical biomarkers and storage for future biomarker discovery and validation studies.

Description:

Objective 1. To determine if actively maintaining an SCPP of at least 65 mmHg with a combination of MAP augmentation and CSF drainage promotes better neurologic recovery than routine hemodynamic management that focuses solely on MAP augmentation. Objective 2. To determine if actively maintaining an SCPP of at least 65 mmHg with a combination of MAP augmentation and CSF drainage will allow for a reduction in the usage of vasopressors in acute SCI. Objective 3. To determine the feasibility of draining CSF to reduce ITP in the acute post-injury setting, when the cord may be swollen against the dura causing subarachnoid space occlusion at the injury site. Objective 4. To determine if there are complications associated with the installation of the intrathecal catheter and drainage of CSF in the acute SCI patient.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 17 Years and older

Eligibility

Inclusion Criteria:

• Male or Female = 17 (or the provincial age of majority - depending on local REB guidelines)
• Complete (AIS A) or incomplete (AIS B, C) acute traumatic spinal cord injury.
• Bony spinal levels between C0 and T12 inclusive.
• Blunt (non-penetrating) spinal cord injury treated either surgically or non-surgically
• Lumbar intrathecal catheter to be inserted as part of clinical hemodynamic management and CSF sample collected within 48 hours of injury
• Initial blood sample collected within 24 hours of injury

Exclusion Criteria:

• Motor incomplete spinal cord injury AIS D (i.e. at least half (half or more) of the key muscle functions below the neurological level of injury (NLI) have a muscle grade greater than or equal to 3/5)
• Spinal cord injury with sensory deficit only (i.e. no motor deficit)
• Penetrating spinal cord injury (including gunshot wounds)
• Isolated radiculopathy
• Isolated cauda equina injury or spinal injury below L1
• Associated injury (soft tissue or bony) to the lumbar spine where the intrathecal catheter would be placed
• Associated traumatic conditions that would interfere with the outcome assessment (e.g., traumatic brain injury, chest, pelvis, abdomen, or femur injury requiring operative intervention)
• Pre-existing neurodegenerative disorder, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis
• Pre-existing thromboembolic disease or coagulopathy, such as hemophilia, von Willebrand disease
• Presence of systemic disease that might interfere with patient safety, compliance or evaluation of the condition under study (e.g., clinically significant cardiac disease, HIV, Hep B or C) HTLV-1
• Pre-existing inflammatory or autoimmune disorder (e.g. rheumatoid arthritis, systemic lupus, psoriasis, or ankylosing spondylitis
• Any other medical condition that in the investigator's opinion would render the protocol procedures dangerous or impair the ability of the patient to receive protocol therapy
• Female patients who are pregnant

Related Conditions & MeSH terms

• Acute Spinal Cord Injury
• Acute Spinal Paralysis
• Paralysis
• Spinal Cord Injuries
• SPINAL Fracture
• Spinal Fractures
• Wounds and Injuries

Intervention

Procedure:
• SCPP Management => 65 mmHg
A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.

Locations

Country	Name	City	State
Canada	Halifax Infirmary - QEII	Halifax	Nova Scotia
Canada	Hopital Du Sacre-Coeur de Montreal	Montreal	Quebec
Canada	St. Michael's Hospital	Toronto	Ontario
Canada	Vancouver General Hospital	Vancouver	British Columbia
United States	University of New Mexico Health Sciences Center	Albuquerque	New Mexico
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Zuckerberg San Francisco General Hospital and Trauma Center	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of British Columbia	Rick Hansen Institute

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Examination	Neurologic recovery over time will be measured using the ISNCSCI examination - at Baseline, Days 1-7, and months 3, 6 and 12. Our primary outcome measure will be the change in total motor score at 6 months post-injury (a time point at which most motor recovery has occurred and is commonly used in acute SCI clinical trials).	12 months
Secondary	Levels of specific biochemical markers in CSF and Blood	CSF and blood samples will be obtained from the intrathecal catheter at 8-hour intervals, three times daily, for 7 days. These samples will be markers that correlate with injury severity and predict neurological outcome.	7 days
Secondary	Spinal Cord Perfusion Pressure (SCPP)	SCPP will be calculated as the difference between the mean arterial pressure and intrathecal pressure. The MAP and ITP will recorded over 7 days post injury.	7 days